A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 14 Dec 2018 Planned number of patients changed from 24 to 30.
- 14 Dec 2018 Planned End Date changed from 17 Jan 2019 to 25 Feb 2019.
- 14 Dec 2018 Planned primary completion date changed from 17 Jan 2019 to 25 Feb 2019.